Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCB | P05771 | 11/20 | 0.62 |
| ▸ | PRKCA | P17252 | 10/20 | 0.62 |
| ▸ | PRKCH | P24723 | 9/20 | 0.62 |
| ▸ | PRKCE | Q02156 | 9/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 9/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 9/20 | 0.62 |
| ▸ | CAMK2D | Q13557 | 5/20 | 0.47 |
| ▸ | CDK4 | P11802 | 4/20 | 0.46 |
| ▸ | CCND1 | P24385 | 4/20 | 0.46 |
| ▸ | PRKACA | P17612 | 4/20 | 0.46 |
| ▸ | PRKACG | P22612 | 4/20 | 0.46 |
| ▸ | PRKACB | P22694 | 4/20 | 0.46 |
| ▸ | CDK2 | P24941 | 4/20 | 0.46 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.46 |
| ▸ | PIM1 | P11309 | 3/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.46 |
| ▸ | PRKCG | P05129 | 2/20 | 0.46 |
| ▸ | CDK1 | P06493 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1030025 | 0.89 | PRKCB (0.51) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL13555831 | 0.86 | PRKCB (0.52) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL1027399 | 0.83 | PRKCB (0.74) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL3541633 | 0.77 | PRKCB (1.00) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL3594020 | 0.76 | PRKCB (1.00) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL855201 | 0.75 | PRKCB (0.70) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL1029391 | 0.74 | PRKCB (0.51) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL2834835 | 0.72 | PRKCB (0.74) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL3602496 | 0.70 | CAMK2D (0.49) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL3605501 | 0.69 | PRKCB (0.54) | PRKCBPRKCAPRKCHPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426440-B2 | Indolymaleimide derivatives | NOVARTIS AG (CH) | 2013-04-23 | — | — | US | disclosed |
| US-8426440-B2 | Indolymaleimide derivatives | NOVARTIS AG (CH) | 2013-04-23 | — | — | US | disclosed |
| US-8426440-B2 | Indolymaleimide derivatives | NOVARTIS AG (CH) | 2013-04-23 | — | — | US | disclosed |
| EP-2246346-B1 | Indolylmaleimide derivatives as protein kinase inhibitors | NOVARTIS AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| EP-1904482-B1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| EP-1904482-B1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| EP-2246346-A1 | Indolylmaleimide derivatives as protein kinase inhibitors | Novartis AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| EP-2246346-A1 | Indolylmaleimide derivatives as protein kinase inhibitors | Novartis AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-20100273774-A1 | INDOLYMALEIMIDE DERIVATIVES | WAGNER JUERGEN | 2010-10-28 | — | — | US | disclosed |
| US-20100273774-A1 | INDOLYMALEIMIDE DERIVATIVES | WAGNER JUERGEN | 2010-10-28 | — | — | US | disclosed |
| US-20100273774-A1 | INDOLYMALEIMIDE DERIVATIVES | WAGNER JUERGEN | 2010-10-28 | — | — | US | disclosed |
| US-7781438-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2010-08-24 | — | — | US | disclosed |
| US-7781438-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2010-08-24 | — | — | US | disclosed |
| US-7781438-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2010-08-24 | — | — | US | disclosed |
| US-20080318975-A1 | Indolylmaleimide Derivatives | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20080318975-A1 | Indolylmaleimide Derivatives | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20080318975-A1 | Indolylmaleimide Derivatives | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| EP-1904482-A2 | INDOLYLMALEIMIDE DERIVATIVES | Novartis AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006533-A2 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006533-A2 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273774-A1 | INDOLYMALEIMIDE DERIVATIVES | IDO1, INMT, IDO2 | PRKCB 2179/4885PRKCA 2904/4885PRKCH 2799/4885 |
| US-20080318975-A1 | Indolylmaleimide Derivatives | IDH3A, INMT, IDH3B | PRKCB 3243/4885PRKCA 4227/4885PRKCH 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.